Abstract
Compared with the healthy cohort, COVID-19 patients showed decreased TSH and FT3 and increased FT4, similar to non-COVID-19 pneumonia. Thyroid function changes were related to the severity of COVID-19. Thyroxine levels have clinical significance for prognosis evaluation, especially FT3.
Introduction
While COVID-19 is primarily a respiratory disease, the SARS-CoV-2 virus is known to affect multiple organ systems. The thyroid gland is a potential target because it expresses high levels of the ACE2 receptor, which the virus uses for entry. Early clinical reports on thyroid function were inconsistent; some suggested direct viral damage (thyroiditis), while others pointed toward a systemic stress response. This systematic review and meta-analysis, published in Frontiers in Endocrinology, synthesizes data from 41 studies to map how COVID-19 disrupts the thyroid gland and determine if hormonal shifts can help clinicians predict patient outcomes.
Methods
The authors conducted a systematic review of English and Chinese databases (including PubMed, Embase, and Cochrane) from the start of the pandemic through August 2022. The analysis included 41 observational studies involving 5,873 COVID-19 patients. Researchers compared COVID-19 patients against healthy cohorts and patients with non-COVID-19 pneumonia, stratifying data by disease severity (severe vs. non-severe) and outcome (survivors vs. non-survivors). Statistical analysis utilized Standard Mean Differences (SMD) and 95% confidence intervals.
Key Results and Insights
The meta-analysis revealed a consistent "thyroid signature" for COVID-19: significantly lower TSH and FT3 levels ($P < 0.001$) and significantly higher FT4 levels ($P < 0.001$) compared to healthy controls.
The NTIS Signature
This observed pattern—low TSH, low FT3, and slightly elevated FT4—is the classic hallmark of Non-Thyroidal Illness Syndrome (NTIS). This suggests that thyroid disruption in COVID-19 is largely a systemic response to the "cytokine storm" and metabolic stress rather than solely direct viral destruction of the gland. Interestingly, these changes were remarkably similar to those seen in non-COVID-19 pneumonia, implying a generalized reaction to severe respiratory distress.
FT3 as a Prognostic Beacon
Of all the markers studied, Free Triiodothyronine (FT3) showed the most dramatic difference between survivors and non-survivors. Survivors had significantly higher levels of TSH (SMD = 0.29), FT3 (SMD = 1.11), and FT4 (SMD = 0.22). In ICU settings, survivors maintained significantly higher FT3 and FT4 levels than non-survivors, reinforcing their value in triaging high-risk patients. Follow-up data showed that thyroid levels generally returned to normal after the acute phase, supporting the transient, stress-induced nature of the condition.
Limitations and Future Work
The authors acknowledge several limitations, including selection bias from hospital-based studies and significant heterogeneity ($I^2 > 80\%$) in some measurements. While the data points toward NTIS, the study cannot entirely rule out direct viral injury to the pituitary-thyroid axis. Future research is needed to determine if thyroid hormone supplementation could improve outcomes in severe COVID-19 cases, though current clinical guidelines generally advise against it for NTIS. Ultimately, thyroxine levels, especially FT3, have significant clinical value for prognosis evaluation in COVID-19.
Summary updated